4OR1 Stock Overview
A biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 3 more risks
Organovo Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.47 |
| 52 Week High | US$1.75 |
| 52 Week Low | US$0.43 |
| Beta | 0.68 |
| 11 Month Change | -9.92% |
| 3 Month Change | -47.96% |
| 1 Year Change | -64.08% |
| 33 Year Change | -91.58% |
| 5 Year Change | -90.12% |
| Change since IPO | -99.42% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4OR1 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -6.5% | -2.0% | 2.6% |
| 1Y | -64.1% | -22.4% | 3.8% |
Return vs Industry: 4OR1 underperformed the German Biotechs industry which returned -22% over the past year.
Return vs Market: 4OR1 underperformed the German Market which returned 4.7% over the past year.
Price Volatility
| 4OR1 volatility | |
|---|---|
| 4OR1 Average Weekly Movement | 11.8% |
| Biotechs Industry Average Movement | 6.3% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.1% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: 4OR1's share price has been volatile over the past 3 months.
Volatility Over Time: 4OR1's weekly volatility has decreased from 19% to 12% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 20 | n/a | www.organovo.com |
Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised of mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company’s lead candidate is FXR314, which is phase 2/3 clinical trial for indication of inflammatory bowel disease with a clinical focus on ulcerative colitis; and completed phase 1 clinical trial for the indication of liver fibrosis with a clinical focus on non-alcoholic steatohepatitis and primary biliary cholangitis.
Organovo Holdings, Inc. Fundamentals Summary
| 4OR1 fundamental statistics | |
|---|---|
| Market cap | €7.87m |
| Earnings (TTM) | -€12.57m |
| Revenue (TTM) | €65.61k |
120.0x
P/S Ratio-0.6x
P/E RatioIs 4OR1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4OR1 income statement (TTM) | |
|---|---|
| Revenue | US$73.00k |
| Cost of Revenue | US$5.24m |
| Gross Profit | -US$5.16m |
| Other Expenses | US$8.82m |
| Earnings | -US$13.99m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.91 |
| Gross Margin | -7,072.60% |
| Net Profit Margin | -19,160.27% |
| Debt/Equity Ratio | 0% |
How did 4OR1 perform over the long term?
See historical performance and comparison